Article
Recent research suggests that the common fusion of two genes may point to a molecular basis for prostate cancer.
Clinical Forum: Advances in low-grade UTUC treatment and care
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
FDA approves integrated sacral neuromodulation system for urinary urge incontinence
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC